Literature DB >> 13678786

Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression.

M Riminucci1, S A Kuznetsov, N Cherman, A Corsi, P Bianco, P Gehron Robey.   

Abstract

Fibrous dysplasia of bone (FD) is caused by somatic mutations of the GNAS1 gene, which lead to constitutive activation of adenylyl cyclase and overproduction of cAMP in osteogenic cells. Previous in vitro studies using nonclonal, heterogeneous strains of FD-derived cells suggested that IL-6 might play a critical role in promoting excess osteoclastogenesis in FD. In this study, we investigated IL-6 expression in FD in situ and its relationship to the actual patterns of osteoclastogenesis within the abnormal tissue. We found that osteoclastogenesis is not spatially restricted to bone surfaces in FD but occurs to a large extent ectopicly in the fibrous tissue, where stromal cells diffusely express IL-6 mRNA and exhibit a characteristic cell morphology. We also observed specific expression of IL-6 mRNA in a proportion of osteoclasts, suggesting that an autocrine/paracrine loop may contribute to osteoclastogenesis in vivo in FD, as in some other bone diseases, including Paget's disease. We also generated homogeneous, clonally derived strains of wild-type and GNAS1-mutated stromal cells from the same individual, parent FD lesions. In this way, we could show that mutated stromal cells produce IL-6 at a basal magnitude and rate that are significantly higher than in the cognate wild-type cells. Conversely, wild-type cells respond to db-cAMP with a severalfold increase in magnitude and rate of IL-6 production, whereas mutant strains remain essentially unresponsive. Our data establish a direct link between GNAS1 mutations in stromal cells and IL-6 production but also define the complexity of the role of IL-6 in regulating osteoclastogenesis in FD in vivo. Here, patterns of osteoclastogenesis and bone resorption reflect not only the cell-autonomous effects of GNAS1 mutations in osteogenic cells (including IL-6 production) but also the local and systemic context to which non-osteogenic cells, local proportions of wild-type vs mutated cells, and systemic hormones contribute.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13678786     DOI: 10.1016/s8756-3282(03)00064-4

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  40 in total

1.  Stromal-derived IL-6 alters the balance of myeloerythroid progenitors during Toxoplasma gondii infection.

Authors:  David B Chou; Brian Sworder; Nicolas Bouladoux; Cindy N Roy; Amiko M Uchida; Michael Grigg; Pamela G Robey; Yasmine Belkaid
Journal:  J Leukoc Biol       Date:  2012-04-09       Impact factor: 4.962

Review 2.  Giant cell tumour of bone: morphological, biological and histogenetical aspects.

Authors:  Mathias Werner
Journal:  Int Orthop       Date:  2006-09-30       Impact factor: 3.075

3.  Disease severity and functional factors associated with walking performance in polyostotic fibrous dysplasia.

Authors:  Scott M Paul; Lisa R Gabor; Scott Rudzinski; David Giovanni; Alison M Boyce; Marilyn R N Kelly; Michael T Collins
Journal:  Bone       Date:  2013-12-04       Impact factor: 4.398

4.  Dental perspectives in fibrous dysplasia and McCune-Albright syndrome.

Authors:  Sunday O Akintoye; Alison M Boyce; Michael T Collins
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-09

5.  Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.

Authors:  Alessandro Corsi; Ernesto Ippolito; Pamela G Robey; Mara Riminucci; Alan Boyde
Journal:  Skeletal Radiol       Date:  2017-06-28       Impact factor: 2.199

Review 6.  Fibrous dysplasia of bone: craniofacial and dental implications.

Authors:  A B Burke; M T Collins; A M Boyce
Journal:  Oral Dis       Date:  2016-09-01       Impact factor: 3.511

7.  Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.

Authors:  Pablo Florenzano; Kristen S Pan; Sydney M Brown; Scott M Paul; Harvey Kushner; Lori C Guthrie; Luis Fernandez de Castro; Michael T Collins; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2019-01-15       Impact factor: 6.741

8.  Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia: A case report.

Authors:  Gui-Dong Li; Akira Ogose; Tetsuo Hotta; Hiroyuki Kawashima; Takashi Ariizumi; Yongjun Xu; Naoto Endo
Journal:  Oncol Lett       Date:  2011-08-02       Impact factor: 2.967

9.  Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor.

Authors:  Masanobu Ohishi; Riccardo Chiusaroli; Michael Ominsky; Frank Asuncion; Clare Thomas; Richa Khatri; Paul Kostenuik; Ernestina Schipani
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

Review 10.  The nature of fibrous dysplasia.

Authors:  Liviu Feller; Neil H Wood; Razia A G Khammissa; Johan Lemmer; Erich J Raubenheimer
Journal:  Head Face Med       Date:  2009-11-09       Impact factor: 2.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.